hVIVO plc (LON:HVO - Get Free Report)'s share price rose 14.9% during trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10 ($0.14). Approximately 45,640,137 shares changed hands during mid-day trading, an increase of 1,091% from the average daily volume of 3,830,527 shares. The stock had previously closed at GBX 8.70 ($0.12).
Wall Street Analyst Weigh In
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research report on Friday, May 30th.
Check Out Our Latest Research Report on hVIVO
hVIVO Stock Up 3.4%
The company's 50 day simple moving average is GBX 15.92 and its 200-day simple moving average is GBX 17.70. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm has a market cap of £76.07 million, a P/E ratio of 4.43 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Research analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Stories
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
